Piramal Pharma announced on Wednesday, January 22, that its division, Piramal Critical Care (PCC), has launched Chlorpromazine Hydrochloride for Injection, USP in the United States. This marks an important addition to PCC’s growing portfolio of generic injectable products. The product will be available in two vial formats: 25 mg/1 mL and 50 mg/2 mL, providing …